Form 4: Karyopharm CEO Paulson Reports PSU Vesting & Tax Sale

Karyopharm Therapeutics CEO Richard Paulson reported the acquisition of shares from vested performance-based restricted stock units and a subsequent tax-related sale.

Summary

• Richard A. Paulson, President and CEO of Karyopharm Therapeutics Inc. (KPTI), reported changes in his beneficial ownership of common stock.
• On September 12, 2025, Mr. Paulson acquired 2,800 shares of common stock at a price of $0.0 per share.
• These shares represent performance-based restricted stock units (PSUs) granted in February 2023, which were earned due to the achievement of a clinical milestone: complete enrollment in the Company's Phase 3 SENTRY trial.
• The achievement of this milestone was certified by the issuer's Compensation Committee on September 12, 2025, and the earned PSUs vested on the same date.
• On September 15, 2025, Mr. Paulson disposed of 1,257 shares of common stock at a price of $6.43 per share.
• This sale was executed pursuant to a durable automatic sale instruction plan adopted on June 10, 2021, and was specifically to satisfy withholding tax liability incurred upon the vesting of the PSUs.
• The sale was not a discretionary trade by Mr. Paulson.
• Following these transactions, Mr. Paulson beneficially owns 84,046 shares of Karyopharm Therapeutics Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the vesting of performance-based restricted stock units, indicating the achievement of a clinical milestone. The subsequent sale is a routine, non-discretionary tax-related event, which does not negatively impact the overall sentiment.

Positives

• The vesting of 2,800 performance-based restricted stock units (PSUs) indicates the successful achievement of a significant clinical milestone: complete enrollment in the Company's Phase 3 SENTRY trial.

Negatives

• A disposition of 1,257 shares occurred, though it was a non-discretionary sale to cover tax obligations related to PSU vesting.

Future Outlook

The filing indicates the successful completion of enrollment for the Phase 3 SENTRY trial, which is a positive step for the company's clinical development pipeline. No other forward-looking statements or guidance are provided.

Management Comments

• The transaction involving the sale of 1,257 shares was effected pursuant to a durable automatic sale instruction plan adopted on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

Industry Context

The successful enrollment in a Phase 3 clinical trial, as indicated by the PSU vesting, is a standard and critical milestone in the biotechnology and pharmaceutical industry, signaling progress in drug development. This aligns with typical industry practices for incentivizing executive performance tied to clinical achievements.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) tied to clinical milestones, such as complete trial enrollment, is a common compensation practice in the biotechnology sector, aligning executive incentives with company-specific R&D progress.
• The execution of a Rule 10b5-1 plan for non-discretionary sales to cover tax liabilities upon equity vesting is a standard and widely accepted practice among executives in publicly traded companies, ensuring compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: The vesting of PSUs and subsequent tax-related sale are routine insider transactions that provide transparency into executive compensation and ownership, with minimal direct impact on the company's operational or financial outlook. The achievement of the SENTRY trial enrollment milestone is a positive for long-term value.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. The vesting of performance-based restricted stock units due to a clinical milestone is a positive operational indicator, but the subsequent tax-related sale is non-discretionary and does not signal a change in management's confidence or the company's fundamental outlook. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate as it provides no new material information to alter a fundamental investment thesis.

Keywords

Karyopharm Therapeutics, KPTI, Richard Paulson, Insider Transaction, Form 4, Restricted Stock Units, PSU, SENTRY trial, Clinical Milestone, Tax Sale, 10b5-1 Plan